Key Points
- Director Madhavan Balachandran sold 10,000 shares of uniQure stock on June 15 for about $278,500, reducing his ownership by 18.78%. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- uniQure shares were trading at $48.16 at the time of the article, well above the stock’s 50-day and 200-day moving averages. The company’s market cap was about $3.04 billion.
- Analysts remain broadly positive on the biotech name, with a Moderate Buy consensus and a $47.17 average price target. Recent coverage was boosted by improved FDA-related outlook for its Huntington’s disease gene therapy program, AMT-130.
uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Jeannette Potts sold 5,237 shares of uniQure stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $27.67, for a total transaction of $144,907.79. Following the completion of the transaction, the insider directly owned 133,246 shares in the company, valued at approximately $3,686,916.82. This represents a 3.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
uniQure Stock Performance
Shares of QURE opened at $48.16 on Thursday. The company has a market capitalization of $3.04 billion, a PE ratio of -13.84 and a beta of 0.98. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The company's fifty day moving average price is $23.55 and its 200 day moving average price is $21.90.
uniQure (NASDAQ:QURE - Get Free Report) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.88) by $0.03. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. As a group, analysts expect that uniQure N.V. will post -3.64 earnings per share for the current year.
Key uniQure News
Here are the key news stories impacting uniQure this week:
- Positive Sentiment: FDA feedback now appears to support a near-term BLA submission for AMT-130, improving the odds of accelerated approval for Huntington’s disease. Reuters
- Positive Sentiment: Cantor Fitzgerald upgraded uniQure to Overweight, citing the improved regulatory outlook and raising its price target to $61. Seeking Alpha
- Neutral Sentiment: The company disclosed insider sales by directors and executives, including recent transactions by Madhavan Balachandran and Jeannette Potts, which may draw attention but were executed under a pre-arranged trading plan in at least one case.
- Neutral Sentiment: Analyst opinions remain mixed overall, with recent price targets ranging widely, showing that expectations for the stock are still highly dependent on FDA and clinical execution.
Analysts Set New Price Targets
QURE has been the subject of a number of recent research reports. Barclays reissued a "positive" rating on shares of uniQure in a report on Wednesday. Cantor Fitzgerald raised uniQure from a "neutral" rating to an "overweight" rating and set a $61.00 target price for the company in a report on Wednesday. Chardan Capital increased their price objective on uniQure from $31.00 to $37.00 and gave the stock a "buy" rating in a research note on Thursday, April 30th. HC Wainwright reiterated a "buy" rating on shares of uniQure in a research note on Thursday. Finally, Mizuho upgraded uniQure from a "neutral" rating to an "outperform" rating and increased their price objective for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, uniQure has an average rating of "Moderate Buy" and an average price target of $47.17.
View Our Latest Research Report on uniQure
Institutional Trading of uniQure
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Militia Capital Management LLC acquired a new stake in shares of uniQure in the first quarter valued at $1,540,000. Flax Pond Capital LLC increased its position in uniQure by 3.8% in the 1st quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company's stock valued at $2,486,000 after acquiring an additional 5,533 shares in the last quarter. Stempoint Capital LP increased its position in uniQure by 79.5% in the 1st quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company's stock valued at $1,276,000 after acquiring an additional 34,581 shares in the last quarter. Irenic Capital Management LP acquired a new stake in uniQure in the 1st quarter valued at about $1,635,000. Finally, Readystate Asset Management LP increased its position in uniQure by 39.6% in the 1st quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company's stock valued at $8,252,000 after acquiring an additional 143,142 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.
uniQure Company Profile
(
Get Free Report)
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
